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A Functional Copy-Number Variation in MAPKAPK2
Predicts Risk and Prognosis of Lung Cancer
Bin Liu,1,2,4 Lei Yang,1,4 Binfang Huang,1,2 Mei Cheng,1 Hui Wang,1 Yinyan Li,1 Dongsheng Huang,1
Jian Zheng,3 Qingchu Li,1 Xin Zhang,1 Weidong Ji,1 Yifeng Zhou,3 and Jiachun Lu1,*
Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2) may promote cancer development and progression by
inducing tumorigenesis and drug resistance. To assess whether the copy-number variation g.CNV-30450 located in the MAPKAPK2
promoter has any effect on lung cancer risk or prognosis, we investigated the association between g.CNV-30450 and cancer risk in three
independent case-control studies of 2,332 individuals with lung cancer and 2,457 controls and the effects of g.CNV-30450 on cancer
prognosis in 1,137 individuals with lung cancer with survival data in southern and eastern Chinese populations. We found that those
subjects who had four copies of g.CNV-30450 had an increased cancer risk (odds ratio ¼ 1.94, 95% confidence interval [CI]¼ 1.61–2.35)
and a worse prognosis for individuals with lung cancer (with a median survival time of only 9 months) (hazard ratio ¼ 1.47, 95%
CI ¼ 1.22–1.78) compared with those with two or three copies (with a median survival time of 14 months). Meanwhile, four copies
of g.CNV-30450 significantly increased MAPKAPK2 expression, both in vitro and in vivo, compared with two or three copies. Our study
establishes a robust association between the functional g.CNV-30450 in MAPKAPK2 and risk as well as prognosis of lung cancer, and it
presents this functional copy-number variation as a potential biomarker for susceptibility to and prognosis for lung cancer.Lung cancer (MIM 211980) ranks as the leading cause of
cancer death in China and worldwide.1 Epidemiological
studies have established many environmental risk factors
for lung cancer, including smoking, air pollution, and radi-
ation.2 All of these factors are stimuli to cells and could
activate the mitogen-activated protein kinase (MAPK)
pathways (Kyoto Encyclopedia of Genes and Genomes
[KEGG] pathway: hsa04010), which are known to regulate
apoptosis, inflammation, and tumorigenesis.3 Therefore,
genetic variation in genes of the MAPK pathway may
influence cancer susceptibility. The MAPK-activated
protein kinase 2 (also known as MAPKAPK2 or MK2
[MIM 602006]) belongs to the p38 MAPK pathway,4 which
is involved in regulating a variety of biological responses
to extracellular signals that include oxidative stress,
radiation, genotoxicity, inflammation, and infection.5
MAPKAPK2 has been identified as oncogenic and involved
in tumor growth and invasion.6,7 Therefore, genetic
variants in MAPKAPK2 may contribute to cancer suscepti-
bility and prognosis.
In the present study, the procedures followed were in
accordance with the ethical standards of the responsible
committee on human experimentation and approved by
the institutional review boards of Guangzhou Medical
University and Soochow University. We performed three
independent case-control studies that included a total of
2,332 individuals with lung cancer and 2,457 controls in
southern and eastern Chinese populations to investigate
the association between copy-number variations (CNVs)
in MAPKAPK2 and cancer risk. After their provision of
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age- (55 years) and sex-frequency-matched healthy con-
trols who were recruited between March 2007 and March
2009 in the Guangzhou area were used as a discovery set,
and 503 individuals with lung cancer and 623 frequency-
matched controls who were enrolled between March 2008
and May 2010 in the Suzhou area were used as the valida-
tion set I. Then, another 773 individuals with lung cancer
and 778 frequency-matched controls who were continu-
ously recruited from the Guangzhou area between April
2009 and June 2011 were employed as the validation
set II. All the individuals were genetically unrelated
Han Chinese. Each participant was scheduled for an inter-
view for collection of data on smoking status, drinking
status, preexisting chronic obstructive pulmonary disease
(COPD) conditions, and other risk factors with a structured
questionnaire (Table S1 available online) and for donation
of a one-time 5 ml peripheral-blood sample.8–10
By searching the Database of Genomic Variants (DGV),
we found that there were three CNVs (g.CNV-2091,
g.CNV-30450, and g.CNV-71062) in MAPKAPK2. Consid-
ering the low frequencies of g.CNV-2091 and g.CNV-
71062 (1/39 ¼ 0.026 and 15/269 ¼ 0.055, respectively),
we selected only g.CNV-30450 (frequency: 6/30 ¼ 0.20),
which spans over the MAPKAPK2 promoter region and
has 1.7 kb sequences (1098~þ668 nt to initiation
transcription code ATG) (Figure S1). Genomic DNA was
extracted from 2 ml whole blood of each participant
and normalized to 20 ng/ml with a good purity (optical
density 260 [OD260]/OD280 ¼ 1.8~2.0). We genotyped
the g.CNV-30450 for all 4,789 subjects by using theisease, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou
y, 1 Tianqiang Road, Guangzhou 510620, China; 3Laboratory of Cancer
China
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Table 1. Distribution of g.CNV-30450 Genotypes of MAPKAPK2 and Associations with the Risk of Lung Cancer
Genotype/Allele
Copy Number
Discovery Set (Southern Chinese) Validation Set I (Eastern Chinese) Validation Set II (Southern Chinese)
Cases
n (%)
Controls
n (%)
Adjusted
OR (95% CI)a
Cases
n (%)
Controls
n (%)
Adjusted
OR (95% CI)a
Cases
n (%)
Controls
n (%)
Adjusted
OR (95% CI)a
Total n of subjects 1,056 1,056 503 623 773 778
Codominant
Modelb
2,751.80 1,526.86 2,122.54
2 709 (67.1) 787 (74.5) 1.00 (ref.) 359 (71.4) 485 (77.8) 1.00 (ref.) 563 (72.8) 591 (76.0) 1.00 (ref.)
3 161 (15.3) 163 (15.4) 1.04 (0.81–1.33) 78 (15.5) 94 (15.1) 1.11 (0.80–1.55) 118 (15.3) 131 (16.8) 0.96 (0.73–1.26)
4 186 (17.6) 106 (10.1) 2.03 (1.54–2.65) 66 (13.1) 44 (7.1) 2.07 (1.38–3.13) 92 (11.9) 56 (7.2) 1.74 (1.22–2.48)
Additive
Modelb
2755.25 1523.66 2122.75
4 versus 3
versus 2
1.34 (1.19–1.52) 1.40 (1.14–1.66) 1.22 (1.04–1.43)
Dominant
Modelb
2,765.03 1,531.12 2,128.443
2 709 (67.1) 787 (74.5) 1.00 (ref.) 359 (71.4) 485 (77.8) 1.00 (ref.) 563 (72.8) 591 (76.0) 1.00 (ref.)
3 þ 4 347 (32.9) 269 (25.5) 1.42 (1.16–1.72) 144 (28.6) 138 (22.2) 1.42 (1.08–1.86) 210 (27.2) 187 (24.0) 1.19 (0.94–1.50)
Recessive
Modelb
2,749.89 1,525.24 2,120.65
2 þ 3 870 (82.4) 950 (90.0) 1.00 (ref.) 437 (86.9) 579 (92.9) 1.00 (ref.) 681 (88.1) 722 (92.8) 1.00 (ref.)
4 186 (17.6) 106 (10.0) 2.01 (1.54–2.63) 66 (13.1) 44 (7.1) 2.04 (1.36–3.06) 92 (11.9) 56 (7.2) 1.75 (1.23–2.51)
The following abbreviations are used: OR, odds ratio; CI, confidence interval; n, number; and ref., reference.
aAdjusted in a logistic-regression model that included age, sex, smoking status, alcohol use, and family history of cancer.
bAkaike information criterion (AIC) value.TaqMan real-time quantitative PCR (qPCR) method
according to the protocol of Applied BioSystems (catalog
no. Hs01173160, Applied BioSystems, Foster City, CA,
USA)11 and validated the results with the AccuCopy assay
(a multiple competitive real-time PCR) by Genesky Bio-
Tech (Shanghai, China) and Affymetrix Genome-Wide
Human SNP Array 6.0 by Bio Miao Biological Technology
(Beijing) in 200 randomly selected samples (Figures S1 and
S2);12 the results were 97.5% or 98.0% concordant.
We detected three kinds of the g.CNV-30450 (i.e., two,
three, and four copies) in blood samples, and found
a significant difference in the distributions of the g.CNV-
30450 genotypes between individuals with lung cancer
and unaffected controls (p ¼ 2.26 3 106) (Table 1). After
adjustment for possible confounding factors including
age, sex, smoking status, drinking status, and family
history of cancer in logistic-regression models, we found
that compared with the common two copies, individuals
who carried four copies had a 2.03-fold increased risk of
lung cancer (odds ratio [OR] ¼ 2.03, 95% confidence
interval [CI] ¼ 1.54–2.65; p ¼ 0.001), but individuals
with three copies did not (p ¼ 0.371), which best fitted
the recessive-genetic model according to the smallest
Akaike information criterion (AIC) value.13 The four copies
conferred a 2.01-fold increased risk of lung cancer
compared with two or three copies (OR ¼ 2.01, 95%
CI ¼ 1.54–2.63; p ¼ 3.1 3 107). We subsequentlyThe Americreplicated the association in the two validation sets, in
which the four copies of g.CNV-30450 contributed to a
2.04-fold increased cancer risk (validation set I: OR ¼
2.04, 95% CI ¼ 1.36–3.06; p ¼ 0.001) and a 1.75-fold
increased lung cancer risk (validation set II: OR ¼ 1.75,
95% CI ¼ 1.23–2.51; p ¼ 0.002). Because the risk associa-
tions observed in the three independent case-control
studies were homogeneous (p ¼ 0.870), we further
combined the three sets to increase the study power for
stratification analysis. We found that the adverse effect of
the four-copy genotype was significant in most subgroups,
except for individuals with a family history of lung cancer,
ever drinkers, and other histological types, which may be
due to limited sample size in these subgroups; however,
there was no significant heterogeneity between the
strata-OR as suggested by the Breslow-Day test (p > 0.05
for all), and no significant interaction between the
MAPKAPK2 adverse genotypes and selected factors
(p > 0.05 for all, Figure S3). Interestingly, in those individ-
uals with a family history of cancer, there was an intui-
tively higher OR than that found in individuals without
a family history of cancer, suggesting that the g.CNV-
30450 explains some of the genetic roles in cancer risk.
Additionally, we found association of the g.CNV-30450
with poor prognosis of lung cancer in 1,137 individuals,
using complete survival data on deaths caused by lung
cancer obtained from the follow-ups conducted everyan Journal of Human Genetics 91, 384–390, August 10, 2012 385
Figure 1. Kaplan-Meier Survival Curve for Individuals with Lung
Cancer by MAPKAPK2 g.CNV-30450 Genotype
(A) The discovery set.
(B) The validation set I.
(C) The validation set II.3 months via telephone from medical records, or from
individuals’ families (Table S2). In the discovery set of
510 individuals with lung cancer, we found that the
median survival time (MST) of individuals who carried
the four-copy-variant genotype in the discovery set was
significantly shorter (9 months) than those with the two-
or three-copy genotype (13 months, log-rank test:
p ¼ 0.001). Similarly, cancer-affected individuals with the
four-copy genotype had an increased hazard of death
(Cox proportional hazards model: hazard ratio [HR] ¼
1.57, 95% CI ¼ 1.22–2.01; p ¼ 4.48 3 105; Figure 1A).
We then confirmed the above results in the validation set
I of 296 individuals and the validation set II of 331 individ-
uals. As shown in Figures 1B and 1C, those carrying four
copies of g.CNV-30450 had a decreased MST by 7 months
compared with the MST for those with two or three copies
(8 months versus 15 months, log-rank test: p ¼ 0.045) and
also had a significant hazard as shown by the Cox model
(HR ¼ 1.48, 95% CI ¼ 1.01–2.17; p ¼ 0.046; Table 2) in
the validation set I, and those with the four-copy genotype
exhibited a shorter MST (7 months) than did those with
the two- or three-copy genotype (15 months), with386 The American Journal of Human Genetics 91, 384–390, August 1a borderline significance (log-rank test: p¼ 0.051) and poor
survival rate (Cox model: HR ¼ 1.53, 95% CI ¼ 0.98–2.39;
p ¼ 0.061; Table 2) in the validation set II. When we
merged all individuals with lung cancer from the three
studies, the four-copy adverse genotype conferred an
MST decreased by 5 months compared with the two- or
three-copy genotype (9 months and 14 months, respec-
tively; log-rank test: p ¼ 9.30 3 106) and had a 47%
higher death risk (Cox model: HR ¼ 1.47, 95%
CI ¼ 1.22–1.78; p ¼ 5.12 3 105; Table 2). Furthermore,
the multivariate Cox model showed that age, smoking
status, stage, surgery, chemotherapy, radiotherapy, and
MAPKAPK2 g.CNV-30450 genotypes remained signifi-
cantly associated with lung cancer survival (Table S3). In
a stratified survival analysis, we found that the association
between four copies of g.CNV-30450 and poor lung cancer
survival was significant in most subgroups, except for
individuals with the histological types of large-cell
carcinoma and small-cell lung cancer. Furthermore, we
did not observe any significant interactions between con-
founding factors or clinical characteristics and g.CNV-
30450 genotypes in lung cancer survival (p > 0.05 for all;
Figure S4).
Previous studies have shown that copy-number aberra-
tions at 1q32, a region that covers human MAPKAPK2,
are associated with increased cancer risk and poor
prognosis.14,15 The gain of human chromosome 1q32 con-
ferred adverse prognosis for atypical meningioma.14,15
With a large population included and three independent
case-control studies, our results consistently showed that
the four-copy genotype of g.CNV-30450 in MAPKAPK2
was associated with an increased risk of lung cancer
compared with the genotype of two or three copies, and
the four copies also conferred a worse prognosis for indi-
viduals with lung cancer. Therefore, the g.CNV-30450
may be a potential biomarker for risk and prognosis of
lung cancer in Chinese populations.
Because the g.CNV-30450 is located in the promoter of
MAPKAPK2, we therefore performed luciferase assays to
show whether the CNV may influence the promoter
activity. Using similar methods to those described previ-
ously,8–10 we constructed two reporter genes integrated
with the single copy or duplicated copies of g.CNV-
30450 into pGL3 luciferase reporter (Figure 2A). Three
human cell lines 16HBE, A549, and NC1-520 were cotrans-
fected with 0.5 mg reporter and 10 ng pRL-TK plasmids. At
16 hr after transfection, wemeasured the luciferase activity
with the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA). The transcription activities of the
reporter genes with dual copies were consistently higher
in 16HBE, A549, and NC1-520 (p < 0.001 for all;
Figure 2B) compared with the reporter gene with a single
copy of the MAPKAPK2 promoter region, suggesting that
the dual copy of g.CNV-30450 may increase the transcrip-
tional activity of MAPKAPK2.
We next detected the MAPKAPK2 expression in 32
primary lung cancer tissues at both mRNA and protein0, 2012
Table 2. Analysis of MAPKAPK2 g.CNV-30450 and Lung Cancer Survival
g.CNV-30450 n Individuals (%) n Deaths MST (months) Log-Rank p Value HR (95% CI)a Cox model p Valuea
Discovery Set 510 413 12
2 352 (69.0) 273 13 0.001 1.00 (ref.)
3 72 (14.1) 63 12 1.17 (0.89–1.55) 0.258
4 86 (16.9) 77 9 1.60 (1.24–2.07) 3.57 3 104
Trend test p value 3.06 3 104
2 þ 3 424 (83.1) 336 13 0.001 1.00 (ref.)
4 86 (16.9) 77 9 1.57 (1.22–2.01) 4.48 3 105
Validation Set I 296 203 13
2 204 (68.9) 133 15 0.105 1.00 (ref.)
3 53 (17.9) 38 13 1.23 (0.84–1.80) 0.278
4 39 (13.2) 32 8 1.58 (1.06–2.33) 0.024
Trend test p value 0.027
2þ3 257 (86.8) 171 15 0.045 1.00 (ref.)
4 39 (13.2) 32 8 1.48 (1.01–2.17) 0.046
Validation Set II 331 208 12
2 228 (68.9) 132 15 0.083 1.00 (ref.)
3 61 (18.4) 41 13 1.28 (0.81–2.03) 0.282
4 42 (12.7) 35 7 1.63 (1.02-2.59) 0.039
Trend test p value 0.028
2 þ 3 289 (87.3) 173 15 0.051 1.00 (ref.)
4 42 (12.7) 35 7 1.53 (0.98–2.39) 0.061
Merged Set 1137 824 12
2 784 (69.0) 538 14 7.07 3 106 1.00 (ref.)
3 186 (16.3) 142 12 1.19 (0.99–1.46) 0.069
4 167 (14.7) 144 9 1.53 (1.26–1.85) 1.56 3 105
Trend test p value 1.08 3 105
2 þ 3 970 (85.3) 680 14 9.30 3 106 1.00 (ref.)
4 167 (14.7) 144 9 1.47 (1.22–1.78) 5.12 3 105
The following abbreviations are used: MST, median survival time; HR, hazard ratio; ref., reference.
aCox regression analysis was adjusted for age, sex, preexisting chronic obstructive pulmonary disease, and smoking, drinking, histology, stages, surgery, chemo-
therapy, and radiotherapy status.levels with SYBR-Green real-time PCR and western blot-
ting, respectively, as described previously.10 The mRNA
expression levels of MAPKAPK2 and an internal reference
b-actin were detected with the ABI Prism 7500 sequence
detection system (Applied BioSystems) with self-designed
primers (Table S4). The MAPKAPK2 protein-expression
levels normalized to that of b-actin were detected with
the Phototope - Horseradish Peroxidase Western Blot
detection kit (Cell Signaling Technology, Danvers, MA,
USA) and were semiquantified with the GeneTools soft-
ware (version 4.01, Syngene, Cambridge). Genotyping of
the g.CNV-30450 in samples of blood and tissue DNA
were detected with the TaqMan qPCR method and vali-
dated with the AccuCopy assay. Expression levels of bothThe AmericmRNA and protein of MAPKAPK2 increased as the copy
numbers of g.CNV-30450 increased, and the four-copy
genotype was associated with significantly increased
MAPKAPK2 mRNA levels (ANOVA test: p ¼ 0.002; linear-
regression test: p < 0.001; Figure 2C) and protein levels
(ANOVA test: p ¼ 0.010; linear-regression test: p ¼ 0.005;
Figures 2D and 2E) in these 32 individuals with lung
cancer. Additionally, we used another 62 paraffin sections
of primary lung cancer tissues from the Second Affiliated
Hospital of Guangzhou Medical University for immuno-
histochemistry to detect the MAPKAPK2 expressions
in situ by using the Image-Pro Plus software (Media Cyber-
netics, Bethesda, MD, USA) to score the MAPKAPK2 cyto-
plasmic expressions. Consistently, individuals carryingan Journal of Human Genetics 91, 384–390, August 10, 2012 387
Figure 2. Functional Analysis of
MAPKAPK2 g.CNV-30450 In Vivo and
In Vitro
(A) Schematic of the two reporter-gene
constructs containing the single or dual
g.CNV-30450.
(B) Luciferase expression of the two
constructs in lung cells (16HBE, A549,
and NCI-520). Student’s t test was used to
test the differences in the expression levels
of different constructs.
(C) The relative mRNA level ofMAPKAPK2
by g.CNV-30450 genotype.
(D) The MAPKAPK2 and b-actin protein
band in lung cancer tissues.
(E) MAPKAPK2 expressions by g.CNV-
30450 genotype. Columns, mean from
three independent experiments; bars, SD.
The copy number of g.CNV-30450 was
from blood DNA. The dual copies of
g.CNV-30450 had significantly higher
luciferase activity than the single copy;
thus, the four copies of MAPKAPK2
g.CNV-30450 had significantly increased
expressions (mean 5 SD) compared with
the two or three copies.the four-copy genotype had a significantly higher
MAPKAPK2-expression score than that of those with
two- and three- copy genotypes (ANOVA test: p ¼ 0.016;
linear-regression test: p ¼ 0.004; Figure S5). These findings
further suggested that the g.CNV-30450 is functional by
inducingMAPKAPK2 expression. Furthermore, it appeared
that the four-copy genotype may be responsible for the
observed CNV in the somatic genome (linear-regression
test: p ¼ 9.95 3 105; Figure S6).
Previous studies showed that overexpression of P38/
MAPKAPK2 pathway signals was common in various
cancers.7,16 When phosphorylated and activated by the
P38 pathway, the active MAPKAPK2 participates in
multiple roles in cell apoptosis,17 cell cycle,18 adhesion,19
movement,20 and response to oxidative stress.6 The
MAPKAPK2 could phosphorylate several other important
cancer-related proteins, such as Cdc25B/C,21 tuberin
(TSC2 [MIM 191092]),18,19 Polo-like kinase 1 (Plk1 [MIM
602098]),22 HSP27,6,20,23 and especially the mRNA-AU-
rich-element (ARE)-binding proteins (i.e., TTP and hnRNP
A0 [MIM 609409]), which further regulate mRNA stability
of multiple genes, such as TNF-a [MIM 191160], CCND1
[MIM 168461], Plk3 [MIM 602913], c-Fos [MIM 164810],
c-Myc [MIM 190080], and MMP-1 [MIM 120353],24,25
affecting cell metabolism, differentiation, and carcinogen-
esis. Meanwhile, MAPKAPK2 can promote tumor growth
and metastasis through the activation of LIM in VEGF-
induced angiogenesis progress.26 MAPKAPK2 also helps
tumor cells in resisting chemotherapy by regulating DNA
repair through operating checkpoint kinase 1 (Chk1
[MIM 603078]) and Chk2 (MIM 603078) in response to
cisplatin, camptothecin, and doxorubicin.27 Genetic varia-
tions inMAPKAPK2, especially in its promoter region, may
influence the gene’s function; therefore, it is biologically
plausible that g.CNV-30450 could increase risk and cause388 The American Journal of Human Genetics 91, 384–390, August 1poor prognosis in individuals with lung cancer by
enhancing the expression of MAPKAPK2, as demonstrated
in the present study.
At present, several CNVs have been reported to be asso-
ciated with human diseases,28 including some systemic
autoimmune diseases29,30 and cancers.31–33 CNVs in the
genome may cause a greater adverse effect on the host
genes’ function than other genetic variants, such as
SNPs, and thus may provide amore effective tool to predict
the risk and prognosis of diseases. In the present study, we
found that the four copies of g.CNV-30450 in MAPKAPK2
are associated with an increased risk and poor prognosis
for lung cancer in Chinese populations, which is probably
caused by an underlying mechanism that increases the
expression of MAPKAPK2 in vivo, and thus promotes
tumorigenesis. In conclusion, our findings suggest that
the g.CNV-30450 in MAPKAPK2 may be a biomarker for
susceptibility to and prognosis for lung cancer.Supplemental Data
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